nilotinib
3 clinical trials
6 abstracts
6 indications
Indication
Chronic Myeloid LeukemiaIndication
Pigmented Villonodular SynovitisIndication
Giant Cell TumorIndication
Tenosynovial Giant Cell TumorIndication
LeukemiaIndication
Chronic MyeloidClinical trial
Multicenter Prospective Trial After 1st or 2nd Unsuccessful Treatment Discontinuation in Chronic Myeloid Leukemia ( CML) Estimating the Efficacy of Nilotinib in Inducing the Persistence of Molecular Remission After Stopping TKI a 2nd or 3rd TimeStatus: Active (not recruiting), Estimated PCD: 2026-09-01
Clinical trial
A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell TumorStatus: Active (not recruiting), Estimated PCD: 2014-04-01
Abstract
Disparities in frontline treatment and overall survival in the era of targeted tyrosine kinase inhibitor therapy for chronic myeloid leukemia: 2004-2021.Org: University of Utah, Huntsman Cancer Institute,
Abstract
ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.Org: South Australian Health and Medical Research Institute, Universitätsklinikum Jena, Akita University Hospital, The University of Texas MD Anderson Cancer Center, University of Chicago,
Clinical trial
Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) - and Quality of Life (QoL) in Elderly Patients (≥60 Years) With Ph+ Chronic Myeloid Leukemia (CML) and MR3.0 / MR4.0 Stable Molecular ResponseStatus: Recruiting, Estimated PCD: 2023-12-31
Abstract
Mortality rate and social disparity trends with tyrosine kinase inhibitory availability in chronic myelogenous leukemia: An analysis in the US from 1999 to 2020.Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Abstract
Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting.Org: University of California San Francisco, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Roswell Park Comprehensive Cancer Center, Hackensack University Medical Center, Portland VA Health Care System and OHSU Knight Cancer Institute,
Abstract
Treatment failure with first line imatinib for patients with chronic myeloid leukaemia in Kenya vs high-income countries.Org: Kenyatta University Teaching, University of Nairobi, Kenyatta National Hospital, Aga Khan University Hospital,
Abstract
Efficacy and safety of ponatinib in management of chronic myeloid leukaemia: Experience from Kenya.Org: Nairobi Hospital Cancer Centre, Kenyatta University Teaching, University of Nairobi, Kenyatta National Hospital, Field Epidemiology and Laboratory Training Programme,